25 recruiting, 16 completed, 4 not yet recruiting, 4 unknown. 30 Phase 2, 18 Phase 1, 6 Early Phase 1, 4 Not applicable, 1 Phase 3.
Follow Leukemia, Plasma Cell: new trials by email Literature Review of Leukemia, Plasma Cell trials Research Report on Leukemia, Plasma Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-09-15 | 2026-09-18 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual-target CAR-T module - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 96 | 2026-03-02 | 2026-04-13 |
| IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma IASO104 - Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL) | Early Phase 1 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2026-02-15 | 2026-01-20 |
| IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia IL-15-armored CAR-T cells - Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | The First Hospital of Jilin University | 25 | 2025-12-29 | 2026-04-03 |
| Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma Isatuximab - Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Recruiting | University of Utah | 40 | 2025-10-09 | 2026-09-11 |
| ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia Autologous hematopoietic stem cell transplantation, BCMA CAR-T, GPRC5D/CD3 BiTEs - Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-08-10 | 2025-08-06 |
| A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia CAR-T cells Infusion chimeric antigen receptor T cells - Relapsed/Refractory Plasma Cell Leukemia, Relapsed/Refractory Multiple Myeloma | Early Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 24 | 2025-07-23 | 2025-10-01 |
| A Study of CT0596 in Plasma Cell Leukemia CAR-T cells Infusion chimeric antigen receptor T cells - Plasma Cell Leukemia | Early Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 27 | 2025-06-25 | 2025-08-01 |
| Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research Metabolically Armed BCMA CAR-T cells. - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Early Phase 1 | Recruiting | Anhui Provincial Hospital | 36 | 2025-06-23 | 2025-07-25 |
| Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia ARI0002h - Leukemia, Plasma Cell | Phase 2 | Not yet recruiting | Fundacion Clinic per a la Recerca Biomédica | 25 | 2025-04-01 | 2025-04-25 |
| Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM BCMA CART - Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2025-03-03 | 2025-08-07 |
| The Norwegian Immunotherapy in Multiple Myeloma Study Teclistamab, Elranatamab, Ciltacabtagene Autoleucel - Myeloma Multiple, Plasma Cell Leukemia | Recruiting | St. Olavs Hospital | 400 | 2025-01-15 | 2026-07-20 | |
| a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia CAR-T cells Infusion - Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | Early Phase 1 | Recruiting | Shanghai Changzheng Hospital | 24 | 2024-12-11 | 2024-12-12 |
| An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia CAR-T（RD140 injection） - Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia | Phase 1 | Not yet recruiting | Peking University People's Hospital | 12 | 2024-10-25 | 2024-10-23 |
| A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia anti-BCMA CAR-T, VRD-based regimen - Plasma Cell Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2023-08-14 | 2025-08-03 |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Itacitinib - Leukemia, Acute, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 32 | 2023-07-06 | 2026-10-07 |
| To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL Human BCMA targeted CAR-NK cells injection - Multiple Myeloma, Plasma Cell Leukemia | Early Phase 1 | Recruiting | Hrain Biotechnology Co., Ltd. | 18 | 2023-07-04 | 2023-09-21 |
| A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia anti-BCMA CAR-T - Plasma Cell Leukemia | Phase 2 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2023-05-23 | 2026-07-01 |
Showing 20 of 58. Sign in to see all of them.
Multiple Myeloma (47) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia, Myeloid, Acute (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Burkitt Lymphoma (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia, Prolymphocytic (6) · Myelodysplastic Syndromes (6) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (5) · Myeloproliferative Disorders (5) · Primary Myelofibrosis (5)
Hemic and Lymphatic Diseases (58) · Immune System Diseases (58) · Immunoproliferative Disorders (58) · Lymphoproliferative Disorders (58) · Neoplasms (58) · Neoplasms by Histologic Type (58) · Hematologic Diseases (56) · Leukemia (56) · Neoplasms, Plasma Cell (54) · Cardiovascular Diseases (47) · Hemorrhagic Disorders (47) · Hemostatic Disorders (47) · Vascular Diseases (47) · Blood Protein Disorders (46) · Paraproteinemias (44)
Dexamethasone (11) · Lenalidomide (9) · Melphalan (9) · fludarabine phosphate (9) · fludarabine (8) · Bortezomib (7) · Cyclophosphamide (7) · Peripheral Blood Stem Cell Transplantation (7) · Whole-Body Irradiation (7) · Mycophenolic Acid (6) · Tacrolimus (5) · Calcium Dobesilate (4) · daratumumab (4) · Filgrastim (3) · Sirolimus (3)
Institute of Hematology & Blood Diseases Hospital, China (8) · Masonic Cancer Center, University of Minnesota (5) · M.D. Anderson Cancer Center (4) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · National Cancer Institute (NCI) (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · The First Affiliated Hospital of Soochow University (2) · University of Utah (2) · AbbVie (1) · Anhui Provincial Hospital (1) · Array Biopharma, now a wholly owned subsidiary of Pfizer (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Biotech (1) · Chunrui Li (1)
United States (31) · China (18) · Italy (3) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Germany (1) · Greece (1) · Ireland (1) · Norway (1) · Portugal (1) · Serbia (1) · South Africa (1) · Spain (1)
Amrita Krishnan (1) · Amy E DeZern, MD (1) · Attaphol Pawarode, MD (1) · Brenda Sandmaier (1) · Bruno Royer, MD (1) · Charlotte Pawlyn (1) · Chunrui Li (1) · Claudio Brunstein, MD (1) · Danai Dima, MD (1) · David Marin, MD (1) · Dehui Zou (1) · Douglas W Sborov (1) · Erica Warlick, MD (1)
PMID 41118600, PMID 28817190, PMID 32499241, PMID 41144785
P30CA015704 (2), 2008 (1), 2019 (1), P01CA015396 (1), P01CA018029 (1), P30CA016672 (1), U10CA180821 (1)